Q4FY21 Result Update - Ipca Laboratories - ICICI Direct

Q4 revenues remained subdued growing just 3.8% YoY to Rs. 1115 crore. Strong YoY growth of 19.7% in export formulations to Rs. 338 crore was partly offset by API sales decline of 5.5% YoY to Rs. 260 crore. Domestic formulations remained flat at Rs. 434 crore vs. Rs. 431 crore in Q4FY20. EBITDA margins improved 484 bps YoY to 20.5% due to better gross margins and lower other expenditure. EBITDA grew 35.8% YoY to Rs. 229 crore. PAT grew 87.5% YoY to Rs. 161 crore (I-direct estimate: Rs. 204 crore). Delta vis-à-vis EBITDA was due to higher other income, lower depreciation and tax rate.

For details, click on the link below: Link to the report

Shares of IPCA LABORATORIES LTD. was last trading in BSE at Rs.2062.6 as compared to the previous close of Rs. 2071.1. The total number of shares traded during the day was 17628 in over 2169 trades.

The stock hit an intraday high of Rs. 2115.5 and intraday low of 2034. The net turnover during the day was Rs. 36589990.

Source : Equity Bulls

Keywords